{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:51:18Z","timestamp":1791492678321,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002560","name":"Soonchunhyang University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Korea Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HC21C0100"],"award-info":[{"award-number":["HC21C0100"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.semarthrit.2026.152921","type":"journal-article","created":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T22:44:11Z","timestamp":1768171451000},"page":"152921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Risk of ILD and safety outcomes across DMARD classes in rheumatoid arthritis and RA-ILD"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7499-6363","authenticated-orcid":false,"given":"Kyung-Ann","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9213-7140","authenticated-orcid":false,"given":"Hyun-Sook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.semarthrit.2026.152921_bib0001","doi-asserted-by":"crossref","first-page":"166","DOI":"10.4078\/jrd.2024.0151","article-title":"Current state and future directions of basic research in rheumatoid arthritis","volume":"32","author":"Ghang","year":"2025","journal-title":"J Rheum Dis"},{"issue":"160","key":"10.1016\/j.semarthrit.2026.152921_bib0002","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0011-2021","article-title":"Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management","volume":"30","author":"Kadura","year":"2021","journal-title":"Eur Respir Rev"},{"issue":"12","key":"10.1016\/j.semarthrit.2026.152921_bib0003","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1002\/art.42640","article-title":"Identification, monitoring, and management of rheumatoid arthritis-associated interstitial lung disease","volume":"75","author":"Koduri","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2026.152921_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103056","article-title":"Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease","volume":"21","author":"Akiyama","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.152921_bib0005","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s40674-024-00217-3","article-title":"Treatment of rheumatoid arthritis-associated interstitial lung disease: an appraisal of the 2023 ACR\/CHEST guideline","volume":"10","author":"Saavedra","year":"2024","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152921_bib0006","unstructured":"Johnson S.R., Bernstein E.J. 2023 American college of rheumatology (ACR)\/American college of chest physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases 2024;76:1182\u2013200."},{"issue":"7","key":"10.1016\/j.semarthrit.2026.152921_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics15070800","article-title":"Impact of csDMARDs vs. b\/tsDMARDs on the prognosis of rheumatoid arthritis-associated interstitial lung disease: a multicenter, retrospective study","volume":"15","author":"Lee","year":"2025","journal-title":"Diagnostics"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.152921_bib0008","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003789","article-title":"Impact of DMARD treatment and systemic inflammation on all-cause mortality in patients with rheumatoid arthritis and interstitial lung disease: a cohort study from the German Rabbit register","volume":"10","author":"Rudi","year":"2024","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152921_bib0009","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13075-024-03362-1","article-title":"Risk factors of mortality in patients with rheumatoid arthritis-associated interstitial lung disease: a single-centre prospective cohort study","volume":"26","author":"Song","year":"2024","journal-title":"Arthritis Res Ther"},{"issue":"17","key":"10.1016\/j.semarthrit.2026.152921_bib0010","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.3390\/diagnostics14171890","article-title":"A systematic review of the key predictors of progression and mortality of rheumatoid arthritis-associated interstitial lung disease","volume":"14","author":"Groseanu","year":"2024","journal-title":"Diagnostics"},{"issue":"5","key":"10.1016\/j.semarthrit.2026.152921_bib0011","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.semarthrit.2013.09.005","article-title":"Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review","volume":"43","author":"Roubille","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.152921_bib0012","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00337-2020","article-title":"Methotrexate and rheumatoid arthritis associated interstitial lung disease","volume":"57","author":"Juge","year":"2021","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.semarthrit.2026.152921_bib0013","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3899\/jrheum.2024-0252","article-title":"Interstitial lung disease in patients with rheumatoid arthritis or psoriatic arthritis initiating biologics and controls: data from 5 Nordic registries","volume":"51","author":"Provan","year":"2024","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152921_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152561","article-title":"Disease-modifying antirheumatic drugs and risk of incident interstitial lung disease among patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"69","author":"Zhang","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.152921_bib0015","first-page":"e15","article-title":"Cohort profile: the National health insurance service-national sample cohort (NHIS-NSC), South Korea","volume":"46","author":"Lee","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152921_bib0016","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/14397595.2021.1906513","article-title":"Pregnancy-associated risk factors and incidence of systemic sclerosis in primiparous women: a nationwide population-based cohort study","volume":"32","author":"Lee","year":"2022","journal-title":"Mod Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2026.152921_bib0017","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1007\/s00296-013-2833-x","article-title":"Development of an algorithm for identifying rheumatoid arthritis in the Korean National Health Insurance claims database","volume":"33","author":"Cho","year":"2013","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.152921_bib0018","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.semarthrit.2020.04.006","article-title":"Validation of claims-based algorithms to identify interstitial lung disease in patients with rheumatoid arthritis","volume":"50","author":"Cho","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"24","key":"10.1016\/j.semarthrit.2026.152921_bib0019","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.semarthrit.2026.152921_bib0020","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1093\/rheumatology\/keac068","article-title":"Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data","volume":"61","author":"Barbulescu","year":"2022","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.152921_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003489","article-title":"Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German Rabbit register","volume":"9","author":"Meissner","year":"2023","journal-title":"RMD Open"},{"issue":"82","key":"10.1016\/j.semarthrit.2026.152921_bib0022","first-page":"1","article-title":"Statistical methods in cancer research. Volume II\u2014the design and analysis of cohort studies","author":"Breslow","year":"1987","journal-title":"IARC Sci Publ"},{"issue":"408","key":"10.1016\/j.semarthrit.2026.152921_bib0023","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1080\/01621459.1989.10478873","article-title":"Regression analysis of multivariate incomplete failure time data by modeling marginal distributions","volume":"84","author":"Wei","year":"1989","journal-title":"J Am Stat Assoc"},{"issue":"457","key":"10.1016\/j.semarthrit.2026.152921_bib0024","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1198\/jasa.2002.s447","article-title":"Modeling survival data: extending the Cox model","volume":"97","author":"Gray","year":"2002","journal-title":"J Am Stat Assoc"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.152921_bib0025","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1214\/aos\/1176345976","article-title":"Cox's regression model for counting processes: a large sample study","volume":"10","author":"Andersen","year":"1982","journal-title":"Ann Stat"},{"key":"10.1016\/j.semarthrit.2026.152921_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152214","article-title":"Risk of venous thromboembolism in Korean patients with rheumatoid arthritis treated with Janus kinase inhibitors: a nationwide population-based study","volume":"61","author":"Song","year":"2023","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152921_bib0027","article-title":"The prevalence and risk factors of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis","volume":"56","author":"Wang","year":"2024","journal-title":"Ann Med"},{"key":"10.1016\/j.semarthrit.2026.152921_bib0028","article-title":"Rheumatoid arthritis-associated interstitial lung disease: advancing the identification and management","volume":"70S","author":"England","year":"2025","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.152921_bib0029","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/S2665-9913(24)00265-0","article-title":"Advanced therapies in US veterans with rheumatoid arthritis-associated interstitial lung disease: a retrospective, active-comparator, new-user, cohort study","volume":"7","author":"England","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152921_bib0030","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s10238-024-01448-3","article-title":"Abatacept versus tumor necrosis factor inhibitors on mortality and medical utilizations in the treatment of rheumatoid arthritis associated interstitial lung disease: a large-scale real-world retrospective cohort study","volume":"24","author":"Shih","year":"2024","journal-title":"Clin Exp Med"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.152921_bib0031","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"ORAL surveillance investigators. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226000107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226000107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:40:43Z","timestamp":1791492043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017226000107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":31,"alternative-id":["S0049017226000107"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.152921","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of ILD and safety outcomes across DMARD classes in rheumatoid arthritis and RA-ILD","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.152921","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152921"}}